Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 14/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132999 | 1.00 | FKBP1A (0.54) | FKBP1AKLK7KLK5CTSLPREP | |
| SCHEMBL31072125 | 1.00 | FKBP1A (0.54) | FKBP1AKLK7KLK5CTSLPREP | |
| SCHEMBL7290929 | 0.86 | FKBP1A (0.55) | FKBP1AKLK7KLK5PREPACE | |
| SCHEMBL25129445 | 0.86 | FKBP1A (0.55) | FKBP1AKLK7KLK5PREPACE | |
| SCHEMBL25133623 | 0.85 | KLK5 (0.55) | FKBP1AKLK7KLK5CTSLACE | |
| SCHEMBL30859278 | 0.85 | KLK5 (0.55) | FKBP1AKLK7KLK5CTSLACE | |
| SCHEMBL19390294 | 0.85 | FKBP1A (0.55) | FKBP1AKLK5PREPACE | |
| SCHEMBL12959279 | 0.85 | FKBP1A (0.55) | FKBP1AKLK5PREPACE | |
| Hydrochloric Acid SCHEMBL7275982 | 0.85 | FKBP1A (0.54) | FKBP1APREPACE | |
| SCHEMBL13413212 | 0.85 | FKBP1A (0.57) | FKBP1APREPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | LERCHEN, HANS-GEORG (DE) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TP53, BRCA1 | FKBP1A 2391/4885KLK7 2841/4885KLK5 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.